Eton Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on the invention and market introduction of medical treatments for rare diseases. Its current product lineup features Biorphen and Rezipres, both phenylephrine injections designed to counter significant hypotension arising from vasodilation during anesthesia. The company also offers Carglumic Acid, a treatment for acute and chronic hyperammonemia linked to N-acetylglutamate Synthase deficiency.